Trial Profile

A Phase 1b/2a proof-of-concept study for plamotamab in multi-drug resistant rheumatoid arthritis (MDR-RA)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Plamotamab (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions; Pharmacodynamics; Proof of concept; Therapeutic Use

Most Recent Events

08 Jan 2026 According to a Xencor media release, the company to provide update on progress achieved in the Phase 1b study of plamotamab in RA in 2H26.
06 Aug 2025 Status changed from planning to recruiting, according to a Xencor media release.
06 Aug 2025 According to a Xencor media release, in June company received regulatory authorization to proceed with the proof-of-concept study of plamotamab.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com